New Inhaled Antibiotic To Treat Respiratory Infections

https://www.europeanpharmaceuticalreview.com/news/67983/polyphor-antibiotic-murepavadin/

Polyphor launches the development of an inhaled antibiotic murepavadin

Polyphor Ltd has announced the development of an inhaled dosage form of its break­through antibiotic Murepavadin. Continue reading New Inhaled Antibiotic To Treat Respiratory Infections

Microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs

ahttps://www.eurekalert.org/pub_releases/2017-10/iuui-imu100517.php

IUPUI microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs

Individuals with cystic fibrosis, or CF, have a high risk of chronic pneumonia because the thick, sticky mucus that builds up in Continue reading Microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs

New Pre-Clinical Data for Iclaprim

Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™

https://globenewswire.com/news-release/2017/10/06/1142163/0/en/Motif-Bio-Presents-New-Pre-Clinical-Data-for-Iclaprim-at-IDWeek-2017.html

1. Pre-Clinical Data Support the Potential Use of Iclaprim in the Treatment of Staphylococcus aureus Pneumonia in Cystic Continue reading New Pre-Clinical Data for Iclaprim

Fighting an old enemy in the battle against cystic fibrosis

http://msutoday.msu.edu/news/2017/fighting-an-old-enemy-in-the-battle-against-cystic-fibrosis/

Published: Aug. 29, 2017

Michael Maiden, a Michigan State University College of Osteopathic Medicine student and doctoral candidate in the Department of Microbiology and Molecular Genetics, was Continue reading Fighting an old enemy in the battle against cystic fibrosis

Phase Two Clinical Trials to treat NTM

http://www.nasdaq.com/press-release/ait-therapeutics-announces-enrollment-of-first-patient-into-its-nontm-abscessus-phase-2-trial-in-20170807-00641

AIT Therapeutics Announces Enrollment of First Patient into Its NO-NTM abscessus Phase 2 Trial in Nontuberculous Mycobacteria (NTM)

10 patients with Mycobacterium Abscessus Complex (MABSC) are expected to enroll in the trial Continue reading Phase Two Clinical Trials to treat NTM

Setting the Record Straight About Coughing Up Blood

https://www.cff.org/CF-Community-Blog/Posts/2017/Setting-the-Record-Straight-About-Coughing-Up-Blood/

Hemoptysis, or coughing up blood, is one of the scariest complications of cystic fibrosis, although it doesn’t have to be. “Hemoptysis” is also the name of a heavy metal band, and that is truly scary! Hemoptysis, the medical Continue reading Setting the Record Straight About Coughing Up Blood

New Drug Application Submitted for Treatment of P. aeruginosa

https://bronchiectasisnewstoday.com/2017/07/28/non-cystic-fibrosis-bronchiectasis-candidate-therpay-nda-submitted-for-linhaliq-for-p-aeruginosa-infection/

New Drug Application Submitted for Linhaliq as Treatment of Pseudomonas Aeruginosa Infection in NCFBE Patients

The pharmaceutical company Aradigm has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq Continue reading New Drug Application Submitted for Treatment of P. aeruginosa

French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic

https://labiotech.eu/antabio-carb-x-cystic-fibrosis/

CARB-X has awarded $8.9M (€7.6M) to Antabio for the development of a new antibiotic against resistant Pseudomonas infections in cystic fibrosis patients.

Antabio is a French company developing new antibiotics to fight the rapidly Continue reading French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic

New Drug Improves Effectiveness of Antibiotics against Drug-resistant Bacteria

Synspira’s Novel Glycopolymer Improves Effectiveness of Antibiotics Against Drug-resistant Bacteria Associated with Cystic Fibrosis

Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, Continue reading New Drug Improves Effectiveness of Antibiotics against Drug-resistant Bacteria